US Patent 9,943,539: Claim Scope, RNAi Coverage, Expiration and Patent Landscape

US Patent 9,943,539 protects a double-stranded chimeric oligonucleotide composition in which the second strand contains at least one defined six-nucleoside modification pattern, XXYYXX. X is an unmodified ribonucleoside and Y is a 2'-O-methyl nucleoside. The patent is directed to composition-level protection for modified siRNA or related duplex oligomers, not to a particular therapeutic target, disease, delivery vehicle, or commercial drug.

The independent claim is technically narrow but commercially relevant. A potentially infringing product must satisfy every limitation in claim 1, including the duplex structure, chimeric nature of both oligomers, target complementarity of the first oligomer, and the XXYYXX motif in the second oligomer.

What does US Patent 9,943,539 claim?

Claim 1 requires a composition containing two hybridized oligomers:

Required element	Claim limitation
Composition	Contains a first oligomer and a second oligomer
Duplex structure	At least part of the first oligomer is hybridized with at least part of the second
Targeting	At least part of the first oligomer is complementary to a selected target nucleic acid
Chemistry	Both oligomers are chimeric oligomers
Second-strand architecture	The second oligomer is a blockmer
Modification motif	The second oligomer contains at least one XXYYXX motif
X residue	Unmodified ribonucleoside
Y residue	Nucleoside with a 2'-OCH3 substituent

The claim does not expressly require:

A particular gene or messenger RNA target
RNA interference activity
A specific therapeutic indication
A lipid nanoparticle
A conjugate, GalNAc ligand, polymer, or other delivery system
A particular sequence
A phosphorothioate backbone
A 3' overhang
A 5' phosphate
A defined formulation or dosage form

Those features appear only in dependent claims or are not claimed at all.

What is the XXYYXX motif in the patent?

The XXYYXX motif is a six-nucleoside sequence pattern:

Position	Required chemistry
1	Unmodified ribonucleoside
2	Unmodified ribonucleoside
3	2'-O-methyl nucleoside
4	2'-O-methyl nucleoside
5	Unmodified ribonucleoside
6	Unmodified ribonucleoside

The motif is defined by chemistry rather than base identity. The claim does not require particular A, C, G, or U bases at the X or Y positions. A sequence can therefore satisfy the motif with multiple base combinations, provided the chemical modification pattern is present.

“Blockmer” is important. The second oligomer is not merely required to contain isolated 2'-O-methyl residues. The claim requires the defined contiguous arrangement of two unmodified ribonucleosides, two 2'-O-methyl nucleosides, and two unmodified ribonucleosides.

Claim 13 broadens the structural requirement within the claim set by requiring at least two XXYYXX motifs.

How do claims 2 through 15 narrow the patent?

The dependent claims impose progressively narrower structural and chemical limitations.

Claim	Added limitation	Commercial significance
2	Each oligomer has about 18 to 30 linked nucleosides	Covers common siRNA lengths and nearby variants
3	Each oligomer has about 21 to 24 linked nucleosides	Targets conventional 21- to 24-mer duplexes
4	Each oligomer has 21 linked nucleosides	Directly covers a standard siRNA length
5	Nucleosides independently selected from unmodified RNA, 2'-O-methyl, and 2'-deoxythymidine	Limits the chemical building blocks
6	First oligomer is antisense and second is sense	Aligns the claim with conventional RNAi terminology
7	Oligomers are a complementary siRNA pair	Makes the RNAi application explicit
8	Linkages are independently phosphodiester or phosphorothioate	Covers mixed-backbone embodiments
9	All linkages are phosphodiester	Narrows the backbone
10	First oligomer has a 5' phosphate	Addresses a common RNAi structural feature
11	At least one oligomer has an overhang	Covers duplexes with non-base-paired terminal residues
12	Each oligomer has a 3' overhang of two 2'-deoxythymidine residues	Covers the classic dTdT siRNA overhang
13	Second oligomer has at least two XXYYXX motifs	Increases chemical pattern density
14	First oligomer lacks an internal DNA segment	Excludes certain DNA-containing chimeras
15	First oligomer is not a deoxy gapmer	Excludes conventional antisense gapmer architecture

Claims 6 and 7 are particularly important for product analysis. They connect the broad duplex composition in claim 1 to a conventional antisense/sense siRNA pair. Claims 12 and 15 help distinguish the claimed subject matter from older DNA-containing antisense technologies.

What products could fall within the patent’s scope?

A product is most closely aligned with the asserted claims if it is a 21-mer or 21- to 24-mer siRNA duplex with the following characteristics:

The antisense strand is complementary to a target RNA.
Both strands contain mixed nucleoside chemistry.
The sense strand includes at least one contiguous XXYYXX motif.
The strands are hybridized.
The duplex uses phosphodiester or phosphorothioate linkages.
The duplex has a 3' dTdT overhang.
The antisense strand has a 5' phosphate.

A hypothetical 21-mer duplex having a sense-strand sequence with the chemical pattern:

RNA-RNA-2'-OMe-2'-OMe-RNA-RNA

could satisfy claim 1 if the remaining limitations are present. The base sequence itself need not match a sequence disclosed in the patent unless another claim or an infringement theory imposes that requirement.

The patent is less likely to read directly on:

A single-stranded antisense oligonucleotide
A duplex in which the second strand lacks XXYYXX
A duplex using only 2'-O-methyl residues without the required block pattern
A duplex in which the first oligomer is a DNA-containing gapmer
A duplex with no target-complementary strand
A DNA/RNA hybrid lacking the required chimeric structure
A product in which the alleged XXYYXX sequence is not contiguous

How strong is the independent claim?

Claim 1 has a meaningful limitation burden. Its principal strength is technical specificity. The claim identifies a concrete structural signature that can be tested through sequence and analytical chemistry.

Its principal weakness is that every element must be proven. A competitor may avoid literal infringement by changing any of the following:

The modification pattern
The strand carrying the motif
The use of unmodified ribonucleosides at the X positions
The use of 2'-O-methyl chemistry at the Y positions
The duplex length or composition
The chimeric architecture
The target-complementarity arrangement

The claim is therefore stronger against products that use the patented modification pattern as a defined manufacturing design and weaker against products that use alternative stabilization chemistries.

The doctrine of equivalents could create additional exposure, but equivalence would depend on the specific substituted chemistry and prosecution history. A materially different modification pattern may present a stronger noninfringement position than a minor positional change.

What formulation patents are covered?

US Patent 9,943,539 does not, based on the supplied claims, claim a formulation. It does not recite:

Lipid nanoparticles
Ionizable lipids
Cholesterol or phospholipids
Polyethylene glycol lipids
Buffer systems
Freeze-dried compositions
Injectable dosage forms
Particle-size specifications
Encapsulation percentages
GalNAc or other targeting ligands

A commercial RNAi product could therefore face separate patent exposure under at least four layers:

Patent layer	Relevance to US 9,943,539
Oligonucleotide chemistry	Directly relevant
Duplex sequence or target	Not required by claim 1
Delivery system	Not claimed in the supplied claims
Formulation and manufacturing	Not claimed in the supplied claims

Freedom-to-operate analysis must separate the active duplex from the delivery platform. A product may avoid this patent but still encounter patents covering lipid nanoparticles, conjugates, manufacturing processes, or target-specific sequences.

Does the patent claim method of use?

No supplied claim is a method-of-use claim. Claims 1 through 15 are composition claims.

The patent does not, in the supplied claim set, require:

Administering the composition
Treating a disease
Silencing a named gene
Reducing a biomarker
Using a particular dose
Delivering the oligomers to a particular tissue

This distinction affects litigation strategy. A composition claim can be asserted against making, using, selling, offering to sell, or importing the claimed composition under 35 U.S.C. § 271. A method-of-use patent would require proof that the claimed treatment method was performed or induced.

When does US Patent 9,943,539 lose exclusivity?

The exact expiration date cannot be determined from the claims alone. US patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension under 35 U.S.C. §§ 154 and 156.

The relevant timeline is:

Event	Date or rule
Patent issuance	April 17, 2018
Ordinary US patent term	20 years from the earliest effective nonprovisional filing date
Patent-term adjustment	May extend the term for USPTO delays
Terminal disclaimer	Could shorten the term if applicable
Patent-term extension	Potentially available for qualifying regulatory review, but not established by the claim text
Post-expiration status	Claims generally cannot support ordinary patent infringement liability after expiration

The issue date does not establish the expiration date. A patent issued in 2018 may expire substantially later or earlier depending on its priority chain and prosecution history. A definitive expiration analysis requires the issued patent’s priority data, PTA certificate, terminal disclaimer record, and any PTE determination.

Is US Patent 9,943,539 an Orange Book patent?

The claims alone do not establish Orange Book listing.

The FDA Orange Book primarily lists patents submitted for approved drug products under the Hatch-Waxman framework. A nucleic-acid composition patent may be listed if it meets FDA listing requirements and is timely submitted by the approved-product holder. Listing depends on the approved product, patent type, submission, and FDA determination, not merely on the patent’s subject matter.

For an siRNA or other nucleic-acid product, relevant regulatory records may also sit outside the conventional small-molecule Orange Book framework. FDA Drugs@FDA identifies approved products, while the Orange Book identifies submitted patent and exclusivity information for eligible products.[2][3]

What Paragraph IV risks exist?

A Paragraph IV challenge is relevant only if the patent is listed in the Orange Book for an approved product and a generic applicant files an abbreviated new drug application referencing that product.

For US Patent 9,943,539, the principal possible Paragraph IV positions would include:

Challenge	Likely theory
Noninfringement	The proposed product lacks XXYYXX, lacks a chimeric oligomer, or fails another claim element
Invalidity for anticipation	Earlier prior art discloses the full duplex and modification pattern
Invalidity for obviousness	Prior art allegedly makes the claimed blockmer arrangement obvious
Written description	The specification may not support the full scope of the chemical and structural genus
Enablement	The claim may allegedly cover more compositions than the disclosure enables
Indefiniteness	A challenger may examine terms such as “blockmer,” “chimeric,” or “at least a portion”

The presence of the patent alone does not establish that a Paragraph IV dispute exists. A Paragraph IV certification, ANDA filing, litigation complaint, or settlement would have to be documented separately.

Which companies may face competitive patent exposure?

The relevant competitive set includes developers and manufacturers of chemically modified RNAi products, including Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, and licensees using their platforms.

The competitive risk is not uniform:

Company or platform type	Exposure to this patent
Conventional 21-mer siRNA with 2'-O-methyl chemistry	Potentially meaningful
GalNAc-siRNA using a different duplex chemistry	Depends on the strand pattern
Lipid nanoparticle siRNA	Duplex claims may apply; delivery patents are separate
Single-stranded antisense products	Generally outside the supplied duplex claims
DNA gapmer antisense products	Specifically disfavored by claim 15
Chemically modified siRNA using alternating patterns other than XXYYXX	Possible design-around
Short hairpin RNA or vector products	Claim applicability depends on whether the final product contains the claimed oligomer pair

Acquisitions and licensing arrangements can transfer enforcement rights without changing the technical scope of the patent. A current ownership and license review must rely on assignment records, merger documents, SEC filings, and relevant litigation dockets.

What manufacturing and IP barriers does the patent create?

The patent can create a manufacturing control point when the claimed duplex is made in the United States or imported into the United States. The relevant evidence may include:

Oligomer sequence records
Modification maps
Batch specifications
Analytical certificates
Mass spectrometry data
Enzymatic digestion data
Manufacturing instructions
Supplier purchase records
Duplex annealing records

The patent does not claim a manufacturing process in the supplied claims. It can still affect manufacturing because the product made by the process may embody the claimed composition.

The most practical design-around options are:

Move the 2'-O-methyl residues to a non-XXYYXX arrangement.
Use a different sugar modification, such as 2'-fluoro or locked nucleic acid, where scientifically acceptable.
Use a single-stranded antisense architecture.
Alter the duplex structure or terminal overhang.
Avoid the claimed combination of unmodified ribonucleosides and 2'-O-methyl residues in the second strand.

Each design-around may create exposure under other patents. A noninfringement position under US 9,943,539 does not establish freedom to operate for the overall product.

What litigation or settlement issues matter?

The supplied claims do not identify litigation, a settlement, a covenant not to sue, or a license. Patent enforcement risk should be assessed separately from claim scope.

Key records include:

USPTO assignment and maintenance records
PACER litigation dockets
PTAB proceedings
Orange Book submissions
ANDA Paragraph IV notices
Product-specific licensing agreements
Patent settlement terms
Terminal disclaimer filings

A settlement could limit enforcement against a particular product or permit entry on a negotiated date without eliminating the patent. A license may also be field-limited, territory-limited, or restricted to a specific sequence, delivery system, or indication.

How does this patent compare with broader RNAi patent estates?

US 9,943,539 is narrower than platform patents claiming broad classes of RNAi agents, target sequences, delivery systems, or conjugates. Its value is concentrated in the chemical architecture of the duplex.

Estate type	Typical subject matter	Relationship to US 9,943,539
Duplex chemistry patents	Modified sense and antisense strands	Closest overlap
Sequence patents	Specific target sequences	Separate layer
Delivery patents	LNPs, GalNAc, conjugates	Not claimed in supplied claims
Formulation patents	Injectable or stabilized formulations	Separate layer
Manufacturing patents	Solid-phase synthesis, annealing, purification	Separate layer
Method-of-use patents	Treatment of named diseases	Not claimed here
Platform patents	Broad RNAi structures and mechanisms	May overlap depending on claim language

The patent’s commercial importance is highest where a product uses a 21-mer or 21- to 24-mer siRNA duplex with the exact 2'-O-methyl block pattern. It is lower for products based on unrelated chemistries or single-stranded antisense designs.

Key Takeaways

US 9,943,539 is a composition patent for a hybridized pair of chimeric oligomers.
Claim 1 requires the second oligomer to contain at least one contiguous XXYYXX motif.
X is an unmodified ribonucleoside; Y is a 2'-O-methyl nucleoside.
Claims 6 and 7 expressly narrow the technology to antisense/sense siRNA embodiments.
Claims 4, 9, 10, and 12 cover a commercially recognizable 21-mer siRNA configuration with phosphodiester linkages, a 5' phosphate, and 3' dTdT overhangs.
The supplied claims do not cover a formulation, delivery vehicle, manufacturing process, disease treatment, or target sequence.
The patent’s exact expiration date cannot be calculated from the claim text or issue date alone.
Paragraph IV exposure depends on Orange Book listing and an ANDA certification.
The most direct design-around strategy is to avoid the claimed XXYYXX chemical pattern or use a different oligonucleotide architecture.
Product clearance requires a layered review of duplex chemistry, target sequence, delivery, formulation, manufacturing, and method-of-use patents.

FAQs

Does US Patent 9,943,539 cover all 2'-O-methyl siRNA?

No. It requires a specific XXYYXX pattern in the second oligomer, in addition to the other limitations of claim 1.

Does the patent cover a 3' dTdT overhang by itself?

No. The dTdT overhang appears in dependent claim 12. A product must also satisfy the limitations inherited from claim 1 and claim 2.

Can a product infringe if the XXYYXX motif is on the antisense strand?

Claim 1 specifies the second oligomer as the blockmer containing the motif. If the motif is only on the first oligomer, literal infringement of claim 1 is less likely unless the product’s strand designation and claim construction produce a different result.

Does a GalNAc-siRNA automatically infringe this patent?

No. GalNAc attachment does not determine infringement. The duplex must independently satisfy the claimed nucleoside, chimeric, hybridization, and motif limitations.

Is a patent license required to launch an siRNA product?

A license may be required if the product falls within an unexpired, enforceable claim and no other legal defense or authorization applies. This patent alone does not establish the complete freedom-to-operate position for an siRNA product.

References

United States Patent No. 9,943,539, claims 1-15 (Apr. 17, 2018).
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
United States Code, 35 U.S.C. §§ 154, 156, 271.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension guidance.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	292141	⤷ Start Trial
Australia	2003213120	⤷ Start Trial
Australia	2003248708	⤷ Start Trial
Australia	2003251524	⤷ Start Trial
Australia	2003287464	⤷ Start Trial
Australia	2003287501	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,943,539

Summary for Patent: 9,943,539